Showing 811-820 of 1612 results for "".
- Skin of Color Society Kicks Off My Best Winter Skin Campaignhttps://practicaldermatology.com/news/skin-of-color-society-kicks-off-my-best-winter-skin-campaign/2462136/The Skin of Color Society (SOCS) has established a national health awareness day known as
- Phase 1 Data: Kymera Therapeutics’ IRAK4 Degrader Shows Promise in AD, HShttps://practicaldermatology.com/news/phase-1-data-kymera-therapeutics-irak4-degrader-shows-promise-in-ad-hs/2462133/Kymera Therapeutics, Inc. KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, is showing early promise in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), according to a Phase 1 Trial
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- Dr. Shawn Kwatra Named New Chair of Dermatology at the UM School of Medicine, Chief of Service of Dermatology at UM Medical Centerhttps://practicaldermatology.com/news/dr-shawn-kwatra-named-new-chair-of-dermatology-at-the-um-school-of-medicine-chief-of-service-of-dermatology-at-um-medical-center/2462002/Shawn Kwatra, MD will become the next Chair of the University of Maryland’s School of Medicine Department of Dermatology and Chief of Service of Dermatology at the University of Maryland Medical Center (UMMC), following a national search. Dr. Kwatra, who will begin
- Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co. Ltd. for Qbrexza in South Korea, Other Asian Nationshttps://practicaldermatology.com/news/journey-medical-corporation-enters-into-an-exclusive-license-agreement-with-maruho-co-ltd-for-qbrexza-in-south-korea-other-asian-nations/2461983/Journey Medical Corporation has entered into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations. Maruho Co., Ltd. is Journey’s exclusive licensing partner that developed and is commercializing Qbrexza (Rapifort) in Japan.&n
- Kenvue Launches Two New Tylenol Precise Pain-relieving Creamshttps://practicaldermatology.com/news/kenvue-launches-two-new-tylenol-precise-pain-relieving-creams/2461973/Kenvue Inc. is rolling out two new topical pain-relieving creams: Tylenol Precise Pain Relieving Cream and Tylenol Precise Cooling Pain Relieving Cream. These are among the first U.S. product launches from Kenvue since it became a publicly traded
- FUE Technique Shows Promise for Treating Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/fue-technique-shows-promise-for-treating-acne-keloidalis-nuchae/2461963/Follicular unit excision (FUE) may help treat acne keloidalis nuchae (AKN), according to research in the Journal of The American Academy of Dermatology – JAAD Case Reports.
- New Kerecis Medical-Fish-Skin Product Approved by Medicare Administrative Contractorshttps://practicaldermatology.com/news/new-kerecis-medical-fish-skin-product-approved-by-medicare-administrative-contractors/2461961/Multiple leading Medicare Administrative Contractors have approved Kerecis Shield, the new fish-skin wound-treatment product. This means that physicians in private clinics will not need to submit invoices for reimbursement, improving efficiency by eliminating a step in the reimbursement proc
- Leprosy Cases Rise in Florida: What Do Dermatologists Need to Know?https://practicaldermatology.com/news/leprosy-cases-rise-in-florida-what-do-dermatologists-need-to-know/2461935/Leprosy is making headlines because of an outbreak in Florida, and although this disease is still rare, it should be on dermatologists' radar, says Carrie Kovarik, MD, a professor of dermatology and medicine at Perelman School of Medicine at the University of Pennsylvania in Philadelphia
- Opzelura Cream Safely Eases AD in Young Kidshttps://practicaldermatology.com/news/opzelura-cream-safely-eases-ad-in-young-kids/2461857/Incyte’s ruxolitinib cream (Opzelura) cleared skin in significantly more kids with atopic dermatitis (AD) than a nonmedicated topical control, a new study shows. The study, which included 300 kids aged ≥2 to <12, met its primary endpoint and showed signi